NCT06845020Not yet recruiting
CSF Proteomic Characterization of Glioblastomas
The Effects of CSF of Patients with Glioblastomas on the Microglial Immune Profile
Source: ClinicalTrials.gov · Last updated 25 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to identify proteins that can be found in the cerebrospinal fluid (CSF) of patients with grade IV brain tumors, specifically glioblastomas, and correlate these proteins with progression free survival, overall survival and performance status (functionality). All participants with high probability of glioblastoma will initially be included, final inclusion will be dependent on the definitive histopathological diagnosis of the tumor. The main question is: Can the researchers identify a proteomic profile in CSF from study participants with glioblastoma in association with a longer progression free survival? Participants will undergo the following procedures, that do not deviate from normal standard diagnostic care. 1. Lumbar puncture to obtain CSF. 2. Blood draw. 3. Trans-surgical tissue sample of the brain tumor. Additionally participants will be planned for follow up appointments every 3 months following the first 12 months after the surgical tumor resection.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 15 (estimated)
- First submitted
- 31 Jan 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Univeridad Autonoma de Guadalajara
- Diseases
- Glioblastoma
- NCT number
- NCT06845020
What you commit to
- Study type: Observational
- Planned participants: 15
- From 1 Mar 2025 to the primary completion date, 28 Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Contamination of the required sample (CSF, serum, tumor).
Other
- Patients who cannot be followed up at the Regional Hospital 'Dr. Valentin Gomez Farias' ISSSTE.
- Patients with whom no sampling was obtained or subjects with incomplete background information.
- Patients who decide to withdraw participation from the study.
Who the study is looking for
- Patients with confirmed diagnosis of glioblastoma (histopathological and molecular).
- Patients who voluntarily accept participation in this study.
- Patients aged 18 or older.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.